Evotec AG - Product Pipeline Review - 2016

Published: Apr, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Evotec AG - Product Pipeline Review - 2016

Summary

Global Markets Direct's, ‘Evotec AG - Product Pipeline Review - 2016', provides an overview of the Evotec AG's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Evotec AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Evotec AG
- The report provides overview of Evotec AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Evotec AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Evotec AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy

- Evaluate Evotec AG's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Evotec AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Evotec AG's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Content
Table of Contents 2

List of Tables 6
List of Figures 6
Evotec AG Snapshot 7
Evotec AG Overview 7
Key Information 7
Key Facts 7
Evotec AG - Research and Development Overview 8
Key Therapeutic Areas 8
Evotec AG - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Evotec AG - Pipeline Products Glance 17
Evotec AG - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Evotec AG - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Evotec AG - Drug Profiles 21
EVT-201 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
EVT-401 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Drug to Inhibit KDM for Oncology 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Drugs for Endometriosis 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
EVT-070 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
EVT-601 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
EVT-701 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
EVT-801 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules for Pain 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Cell Therapy for Type 1 Diabetes and Type 2 Diabetes 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drug for Kidney Diseases 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Drugs for Alzheimer's Disease 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drugs for Multiple Sclerosis 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drugs for Tissue Fibrosis 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drugs to Inhibit FGFR3 for Bladder Cancer 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Induced Pluripotent Stem Cells for Amyotrophic Lateral Sclerosis 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Chronic Kidney Disease 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules for Dysferlinopathies 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules for Glioblastoma Multiforme 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules for Huntington Disease 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Inflammation 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules for Multiple Sclerosis 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules for Neurodegenerative diseases 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules for Solid Tumor 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit PGB for Bacterial Infections 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Evotec AG - Pipeline Analysis 50
Evotec AG - Pipeline Products by Target 50
Evotec AG - Pipeline Products by Route of Administration 51
Evotec AG - Pipeline Products by Molecule Type 52
Evotec AG - Pipeline Products by Mechanism of Action 53
Evotec AG - Recent Pipeline Updates 54
Evotec AG - Dormant Projects 55
Evotec AG - Discontinued Pipeline Products 56
Discontinued Pipeline Product Profiles 56
EVT-301 56
sembragiline 56
ocaperidone 56
REN-1654 56
REN-213 56
REN-850 56
Evotec AG - Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

Evotec AG, Key Information 7
Evotec AG, Key Facts 7
Evotec AG - Pipeline by Indication, 2016 9
Evotec AG - Pipeline by Stage of Development, 2016 11
Evotec AG - Monotherapy Products in Pipeline, 2016 12
Evotec AG - Partnered Products in Pipeline, 2016 13
Evotec AG - Partnered Products/ Combination Treatment Modalities, 2016 14
Evotec AG - Out-Licensed Products in Pipeline, 2016 15
Evotec AG - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Evotec AG - Phase II, 2016 17
Evotec AG - Phase I, 2016 18
Evotec AG - Preclinical, 2016 19
Evotec AG - Discovery, 2016 20
Evotec AG - Pipeline by Target, 2016 50
Evotec AG - Pipeline by Route of Administration, 2016 51
Evotec AG - Pipeline by Molecule Type, 2016 52
Evotec AG - Pipeline Products by Mechanism of Action, 2016 53
Evotec AG - Recent Pipeline Updates, 2016 54
Evotec AG - Dormant Developmental Projects,2016 55
Evotec AG - Discontinued Pipeline Products, 2016 56
Evotec AG, Subsidiaries 57